T

Telomir Pharmaceuticals Inc
NASDAQ:TELO

Watchlist Manager
Telomir Pharmaceuticals Inc
NASDAQ:TELO
Watchlist
Price: 1.4325 USD -1.21%
Market Cap: 49.2m USD

Telomir Pharmaceuticals Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Telomir Pharmaceuticals Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
T
Telomir Pharmaceuticals Inc
NASDAQ:TELO
Research & Development
-$2.2m
CAGR 3-Years
-160%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Research & Development
-$15.7B
CAGR 3-Years
-2%
CAGR 5-Years
-7%
CAGR 10-Years
-6%
Bristol-Myers Squibb Co
NYSE:BMY
Research & Development
-$9.7B
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
-7%
Pfizer Inc
NYSE:PFE
Research & Development
-$10.1B
CAGR 3-Years
6%
CAGR 5-Years
-4%
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Research & Development
-$15.5B
CAGR 3-Years
-10%
CAGR 5-Years
-10%
CAGR 10-Years
-8%
Eli Lilly and Co
NYSE:LLY
Research & Development
-$12.6B
CAGR 3-Years
-21%
CAGR 5-Years
-17%
CAGR 10-Years
-11%
No Stocks Found

Telomir Pharmaceuticals Inc
Glance View

Market Cap
48.5m USD
Industry
Pharmaceuticals

Telomir Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Tampa, Florida and currently employs 2 full-time employees. The company went IPO on 2024-02-09. Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The firm is focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. TELOMIR-1 serve as a metal enzyme inhibitor of essential metals such as zinc and copper. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The Company’s BioMAP platform provides an unbiased, target-agnostic, and data-driven approach to understanding the effect of mono- or combination therapies on human disease models and translational biomarkers.

TELO Intrinsic Value
Not Available

See Also

What is Telomir Pharmaceuticals Inc's Research & Development?
Research & Development
-2.2m USD

Based on the financial report for Dec 31, 2024, Telomir Pharmaceuticals Inc's Research & Development amounts to -2.2m USD.

What is Telomir Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-160%

Over the last year, the Research & Development growth was -42%. The average annual Research & Development growth rates for Telomir Pharmaceuticals Inc have been -160% over the past three years .

Back to Top